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case, the costs of therapy are partly offset by reducing the frequency of relapses and 
the progression of the disease.
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OBJECTIVES: Treatment failure patients in various disease areas are often treated by 
multiple rounds of therapy. However, new treatment options are emerging that have 
potential to replace that treatment with single-agent or single round of combination 
treatment. It is challenging to demonstrate cost-effectiveness of these new agents, 
especially when comparator is not one single regimen but sequential treatment. We 
present here our results from a study where we developed a model that can incorporate 
multiple rounds of treatment or relapses to estimate cost-effectiveness of new emerging 
therapies. METHODS: Intervention was chosen as an emerging T-cell lymphoma drug 
candidate. Comparator was chosen as sequential treatment with 1–5 chemo regimens 
(called DHAP, ESHAP, ICE, HyperCVAD, and EPOCH). All comparator chemo regi-
mens are generics and their prices were obtained from Medispan’s PriceRx. Interven-
tion’s price was assumed as median price of branded chemotherapy agents. Cost, 
efﬁ cacy, adverse events, and utilities were sourced and estimated from published 
studies for T and B-cell lymphoma. Relapses and number of chemo regimens for 
comparators were varied from 1–5. Sensitivity analyses were performed for all base 
calculations. RESULTS: Model results show that a new agent that can replace multiple 
rounds of treatment is relatively more cost-effective than another agent that replaces 
relatively fewer rounds of treatments. Our base-case incremental cost-effectiveness 
with one chemo regimen as comparator was $262,908. However, if there are 2,3,4, 
or 5 sequential rounds, the ICER values change to $223,078, $183,249, $143,420, 
and $103,591, respectively. CONCLUSIONS: For newer agents that are indicated for 
treatment failure patients, the use of sequential treatments as comparator can signiﬁ -
cantly improve their cost-effectiveness. The model approach described here can be 
used for arthritis, hepatitis C, and diabetes and oncology TF patients.
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OBJECTIVES: FOLFOX (folic acid [l-LV], 5-FU, and oxaliplatin) is a standard 
therapy for metastatic colorectal cancer. FOLFOX in adjuvant therapy was approved 
in 2009. However, cost-effectiveness of FOLFOX, which can prolong DFS (disease-
free survival), is not known. METHODS: We performed cost-effectiveness analysis of 
FOLFOX in adjuvant therapy for stage3 colon cancer compared with FU/LV as a 
standard regimen. Our analysis is based on the patient-level data of MOSAIC (the 
Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adju-
vant Treatment of Colon Cancer) trial. Survival curve of DFS and OS (overall survival) 
was extrapolated by cure model, which uses parametric regression considering some 
patients can cure without recurrence. Death of any other causes was treated as compet-
ing risk. Expected value of mean survival year was gained by calculating area under 
the estimated survival curve during 15 years. QALY (quality-adjusted life-year) was 
calculated weighting survival time by utility scores. Since our analysis is from the 
perspective of health-care payer, only direct medical costs were included. Three percent 
annual discount rate was used for both costs and outcome. RESULTS: Adjuvant 
FOLFOX therapy for stage 3 colon cancer patients can gain more QALY than stan-
dard FU/LV therapy. The difference of both therapies is about 0.5 QALY. ICER 
(incremental cost-effectiveness ratio) of FOLFOX compared with FU/LV estimated to 
be less than JPY 2.5 million (US$28,000, US$ 1 = JPY 90) per QALY. This value is 
thought to be a little conservative because time horizon of our analysis is 15 years, 
not lifetime to avoid uncertainty of long-term future. CONCLUSIONS: FOLFOX 
therapy in adjuvant of stage 3 colon cancer is cost-effective. The ICER compared with 
FU/LV is acceptable from the Japanese health-care payer.
PCN81
COST-EFFECTIVENESS ANALYSIS OF THREE STRATEGIES OF 
ERLOTINIB TREATMENT IN NON0-SMALL-CELL LUNG CANCER: A 
PROSPECTIVE MULTICENTRIC FRENCH STUDY (ERMETIC)
Borget I1, Cadranel J2, Mauguen A1, Coudert B3, Dansin E4, Friard S5, Daniel C6, Quoix E7, 
Madelaine J8, Madroszyk A9, Morin F10, Pignon JP1, Chouaid C11
1Institut Gustave Roussy, Villejuif, France; 2Hospital Tenon, PARIS, France; 3CLCC Dijon, 
Dijon, France; 4CHU Lille, Lille, France; 5Hospital Foch, Suresnes, France; 6Institut Curie, Paris, 
France; 7CHU Strasbourg, Strasbourg, France; 8CHU Caen, Caen, FRANCE, France; 9CLCC 
Marseille, Marseille, France; 10IFCT, Paris, France; 11Hôpital St Antoine, Paris, France
OBJECTIVES: Although several clinical and biological parameters are prognostic 
factors of NSCLC patients outcome, their medico-economic impact in the prescription 
of erlotinib has never been evaluated. a French NCI prospective study aimed to 
compare cost and effectiveness of three strategies of erlotinib initiation in second line 
or more treatment of advanced NSCLC patients: initiation in all patients, patients 
selected on clinical-guided strategy, and patients selected on biological-guided strategy. 
METHODS: A Markov model compared the outcomes and costs (limited to direct 
medical costs from the third-party payer perspective) of a prospective multicentric 
cohort of consecutive advanced NSCLC patients newly treated by erlotinib, to a cohort 
of clinical-selected patients (non/ex-smoking women with adenocarcinoma histology) 
and a cohort of biomarker-selected patients (EGFR mutation). Utility data were 
extracted from literature. Sensitivity analyses were performed. RESULTS: A total of 
522 patients were enrolled between March 2007 and March 2008. Median age was 
63 years; 32% were females; 65% had adenocarcinoma; and 8% had EGFR mutation. 
The strategy which consists to treat all patients was dominated, as it was both the less 
effective and the most expensive strategy (0.495 QALY/c22,396). The clinical-guided 
strategy was slightly more effective than the biological-guided strategy (respectively 
0.568 and 0.563 QALY), but it was also more expensive (respectively c16,299 and 
c15,187). The dominant strategy was then the biological-guided strategy (c26,975/
QALY). The model was robust to variations of biological exam costs, palliative costs, 
and utility data. Biological-guided strategy appears the most effective and the less 
expensive strategy when the prevalence of EGFR mutation exceeds 10%. CONCLU-
SIONS: Biological-guided strategy appears the dominant strategy if the prevalence of 
EGFR mutation was >10%. This suggests determining EGFR mutation status in prior-
ity to non/former smokers, females with adenocarcinoma.
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OBJECTIVES: The Center for Comparative Effectiveness Research in Cancer Genom-
ics (CANCERGEN) is a multidisciplinary, national consortium established to conduct 
CER in Genomics and Personalized Medicine (GPM). The objective was the evaluation 
and prioritization of GPM applications for study in a prospective, randomized CER 
trial. METHODS: Candidate GPMs were identiﬁ ed through a landscape analysis of 
recent literature. Initial candidates were examined by cancer genomics experts and 
study investigators to identify 5–7 GPMs for evaluation by a diverse group of external 
stakeholders, including representatives from patients groups, payers, test developers, 
state-funded public HTA programs, and practicing oncologists. We developed Topic 
Briefs and Test Target Proﬁ les assessing the following domains: population impact, 
current standard of care, clinical validity, potential beneﬁ ts, potential harms, economic 
impact, evidence of need, trial feasibility, and current payer status. RESULTS: We 
identiﬁ ed 43 studies from 183 GPMs based on our landscape analysis, which were 
narrowed to four GPMs through feedback from cancer genomics experts; two addi-
tional GPMs were identiﬁ ed by investigators from our clinical trials consortium 
(SWOG). The six GPMs included: ERCC1 testing for platinum chemotherapy in 
NSCLC, EGFR mutation testing for TKIs in NSCLC maintenance, tumor markers for 
breast cancer recurrence, EGFR FISH testing for ﬁ rst-line cetuximab in NSCLC, BRAF 
testing in colorectal cancer, and gene expression proﬁ ling in multiple myeloma. Exter-
nal stakeholders preliminarily identiﬁ ed the ﬁ rst three of these as most likely providing 
the greatest value of research. CONCLUSIONS: A rapid process for research priori-
tization involving literature evaluation, expert input, and stakeholder feedback is 
feasible with adequate resources and processes. Elements include an organization 
facilitating collaboration between investigators with CER/clinical trials experience, 
and utilizing systematic and timely evidence-assessment accessible to stakeholders. 
Final selection of a GPM for study in a prospective CER trial will be based on quan-
titative value-of-information analyses, implementation feasibility, and funding mecha-
nisms, including coverage with evidence development.
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BACKGROUND: Androgen deprivation therapy (ADT) decreases bone mineral 
density (BMD), increasing risk of fragility fractures and decreasing quality of life over 
time. Until recently, there were no licensed treatments despite high unmet medical 
need. In a randomized, double-blind, placebo-controlled trial, denosumab increased 
BMD and reduced the incidence of vertebral fractures in nonmetastatic PrCa patients 
receiving ADT. OBJECTIVES: To assess the cost-effectiveness (CE) of denosumab 
versus no treatment in nonmetastatic PrCa CTIBL patients in Sweden. METHODS: 
A Markov model was adapted from previously developed models in osteoporosis. This 
includes six fracture states: hip, vertebral, wrist, other, post-hip, and post-vertebral 
fracture. Model inputs were based on a literature review conducted in PUBMED. The 
target population reﬂ ected patient characteristics of the trial. The model horizon was 
5 years, reﬂ ecting progression to metastatic disease. General population fracture risks 
from Swedish males were adjusted by the relative risk of fracture due to ADT. Only 
the efﬁ cacy of denosumab on vertebral fractures was included in the base case. a 
societal perspective was used. Published trial data were used to validate the model in 
terms of fractures. RESULTS: The cost per QALY (ICER) for denosumab versus no 
treatment ranged from c46,683 to c58,282. Multiple deterministic sensitivity analyses 
(SA) were performed. The main driver of CE was the efﬁ cacy of denosumab; when it 
